Anti-inflammatory effects of tanshinone IIA on atherosclerostic vessels of ovariectomized ApoE mice are mediated by estrogen receptor activation and through the ERK signaling pathway

Cellular Physiology and Biochemistry

Volumn 35, Issue 5, 2015, Pages 1744-1755

  Liu, Xin ^a   Guo, Chun Yu ^a   Ma, Xiao Juan ^a   Wu, Cai Feng ^a   Zhang, Ying ^a   Sun, Ming Yue ^a   Pan, Yu Ting ^b   Yin, Hui Jun ^a  

^a XIYUAN HOSPITAL   (China)

^b GANSU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

17 estradiol; Anti inflammation; ApoE mice; Atherosclerosis; ERK1 2; ICI182780

Indexed keywords

ALDEHYDE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; METHANE DICARBOXYLIC ALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; SUPEROXIDE DISMUTASE; SYNAPSIN I; TANSHINONE IIA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ABIETANE DERIVATIVE; APOLIPOPROTEIN E; NONSTEROID ANTIINFLAMMATORY AGENT; TANSHINONE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; ESTRADIOL BLOOD LEVEL; FEMALE; LIPID BLOOD LEVEL; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMISTRY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIPID DIET; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; ESTRADIOL; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OVARIECTOMY; OXIDATIVE STRESS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TRIGLYCERIDES;

EID: 84926153381     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373986     Document Type: Article

References (49)

1. American Heart Association: Heart and stroke statistical update, Dallas, Texas. AHA, 1999.
2. Mohle-Boetani J, Whittemore A: Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
3. Caulin-Glaser T, Farrell WJ, Pfau SE, Zaret B, Bunger K, Setaro JF, Brennan JJ, Bender JR, Cleman MW, Cabin HS, Remetz MS: Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;31:1555-1560.
4. Koh KK, Bui MN, Mincemoyer R, Cannon RO 3rd: Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997;80:1505-1507.
5. Rodríguez E, López R, Paez A, Massó F, Montano LF 17Beta-estradiol inhibits the adhesion of leukocytes in TNF-alpha stimulated human endothelial cells by blocking IL-8 and MCP-1 secretion, but not its transcription. Life Sci 2002;71:2181-2193.
6. Castanho VS, Nakamura RT, Pinto-Neto AM, Faria EC: Postmenopausal therapy reduces catalase activity and attenuates cardiovascular risk. Arq Bras Cardiol 2012;11,9:1008-1014.
7. Haas MJ, Raheja P, Jaimungal S, Sheikh-Ali M, Mooradian AD. Estrogen-dependent inhibition of dextroseinduced endoplasmic reticulum stress and superoxide generation in endothelial cells. Free Radic Biol Med 2012;52:2161-2167.
8. Darabi M, Ani M, Movahedian A, Zarean E, Panjehpour M, Rabbani M: Effect of hormone replacement therapy on total serum anti-oxidant potential and oxidized LDL/ß2-glycoprotein I complexes in postmenopausal women. Endocr J 2010;57:1029-1034.
9. Li F, Yu X, Szynkarski CK, Meng C, Zhou B, Barhoumi R, White RE, Heaps CL, Stallone JN, Han G: Activation of GPER Induces Differentiation and Inhibition of Coronary Artery Smooth Muscle Cell Proliferation. PLoS One 2013;8:e64771.
10. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Senzaki K, Moriya T, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H: Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol 2004;219:17-26.
11. Ueda K, Lu Q, Baur W, Aronovitz MJ, Karas RH: Rapid estrogen receptor signaling mediates estrogeninduced inhibition of vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 2013;33:1837-1843.
12. Lemay A: The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 2002;24:711-715.
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
14. Rosano GM, Vitale C, Fini M: Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann N Y Acad Sci 2006;1092:341-348.
15. Simon JA: What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15:3-10.
16. Libby P : Inflammation in atherosclerosis. Nature 2002;420:868-874.
17. Stocker R, Keaney JF Jr. :Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
18. Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M: Fluvastatin reduces modification of lowdensity lipoprotein in hyperlipidemic rabbit loaded with oxidative stress. Eur J Pharmacol 2002;436:97-105.
19. Cheng, T.O: Cardiovascular effects of Danshen. Int J Cardiol 2007;121:9-22.
20. Wan AK, Leung SW, Zhu DY, Man RY: Vascular effects of different lipophilic components of "Danshen", a traditional Chinese medicine, in the isolated porcine coronary artery. J Nat Prod 2008;71:1825-1828.
21. Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, Shen X, Huang H, Cai Y, Tang F, Wang H, Liu P: Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys 2011;515:72-79.
22. Chen W, Tang F, Xie B, Chen S, Huang H, Liu P: Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol 2012;674:359-364.
23. Fang ZY, Lin R, Yuan BX, Liu Y, Zhang H:Tanshinone IIA inhibits atherosclerotic plaque formation by downregulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci 2007;81:1339-1345.
24. Fang ZY, Lin R, Yuan BX, Yang GD, Liu Y, Zhang H: Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit. J Ethnopharmacol 2008;115:217-222.
25. Fan GW, Gao XM, Wang H, Zhu Y, Zhang J, Hu LM, Su YF, Kang LY, Zhang BL: The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol 2009;113:275-280.
26. Li X, Du JR, Yu Y, Bai B, Zheng XY: Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. J Ethnopharmacol 2010;129:273-279.
27. Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, Gao J, Chen S, Bao L, Huang H, Liu P: Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol 2007;46:427-438.
28. Liang X, He M, Chen T, Wu Y, Tian Y, Zhao Y, Shen Y, Liu Y, Yuan Z:17ß-estradiol suppresses the macrophage foam cell formation associated with SOCS3. Horm Metab Res 2013;45:423-429.
29. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N: Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/-mice. J Clin Invest 2001;107:333-340.
30. Liu Z, Wang J, Huang E, Gao S, Li H, Lu J, Tian K, Little PJ, Shen X, Xu S, Liu P: Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. J Lipid Res 2014;55:201-213.
31. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M: Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009;16:4654-4667.
32. Verreth W, De Keyzer D, Davey PC, Geeraert B, Mertens A, Herregods MC, Smith G, Desjardins F, Balligand JL, Holvoet P: Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol 2007;151:347-355.
33. Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, Gao J, Chen S, Bao L, Huang H, Liu P Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress Vascul Pharmacol 2007 46 427-438
34. Chen W, Tang F, Xie B, Chen S, Huang H, Liu P: Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol 2012;674:359-364.
35. Kriszbacher I, Koppan M, Bodis J: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;353:429-430.
36. Steffens S, Mach F: Inflammation and Atherosc-lerosis. Herz 2004;29:741-748.
37. Nabel EG: Biology of the impaired endothelium. Am J Cardiol 1991;68:6C-8C.
38. Balanescu S, Calmac L, Constantinescu D, Marinescu M, Onut R, Dorobantu M: Systemic inflammation and early atheroma formation: are they related? Maedica 2010;12,5:292-301.
39. Tang C, Xue HL, Bai CL, Fu R: Regulation of adhesion molecules expression in TNF-a-stimulated brain microvascular endothelial cells by tanshinone IIA: involvement of NF-B and ROS generation. Phytother Res 2011;25:376-380.
40. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 2006;542:1-7.
41. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
42. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
43. Cano E, Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995;20:117-122.
44. Han C, Liu J, Liu X, Li M: Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis 2010;212:206-242.
45. Lu YG, Fu CH, Yan H: Atorvastatin suppressing endothelial microparticles-inducing upregulation of ICAM-1 in HUVECs by ERK1/2 signal pathway. Chin J Gerontol 2012;3:979-981.
46. Duan JH, Xu HS, Dai SL: Phytoestrogen a-Zearalanol inhibition of oxLDL -induced endothelin-1 gene expression and antioxidation. Chin Pharmacol Bull 2006;22:930-934.
47. Ling S, Zhou L, Li H, Dai A, Liu JP, Komesaroff PA, Sudhir K: Effects of 17-estradiol on growth and apoptosis in human vascular endothelial cells: Influence ofmechanical strain and tumor necrosis factor-a. Steroids 2006;71:799-808.
48. Guanwei Fan, Yan Zhu, Hao Guo: Direct Vasorelaxation by a Novel Phytoestrogen Tanshinone IIA Is Mediated by Nongenomic Action of Estrogen Receptor Through Endothelial Nitric Oxide Synthase Activation and Calcium Mobilization. J Cardiovasc Pharmacol 2011;3:340-347.
49. Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, Xu SW, Liu WH, Liu PQ, Huang HQ: Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 2011;650:275-284.